Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Conditions: Type 1 Diabetes Mellitus With Diabetic Nephropathy
Interventions: Drug: Sotagliflozin; Drug: Ambrisentan; Drug: Ambrisentan and Sotagliflozin
Sponsors: University Medical Center Groningen; Juvenile Diabetes Research Foundation; Lexicon Pharmaceuticals
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments